Discover the latest advances in hormone research and clinical endocrinology at ENDO 2026. This year’s conference, taking place in Chicago, Ill., June 13-16, 2026, is designed to enhance your knowledge and skills in endocrinology with a mix of programs for both the clinician and researcher. With an extensive program covering a broad array of topics,...
Whether to treat low testosterone in men with obesity will be the topic of “Low Testosterone in Obesity: Should We Treat or Not?” a debate session at ENDO 2026 that is sure to be somewhat vigorous as two experts in the field take sides in a session moderated by Endocrine Society Past-President Stephen Hammes, MD,...
The Endocrine Society and Keystone Symposia are partnering to hold a series of joint translation scientific meetings that connect foundational (or basic) science with clinical practice across oncology, cardiometabolism, and diabetes with the aim of supporting a full bench-to-bedside and back research cycle. Keystone Symposia contributes deep connections to basic scientists and a robust infrastructure...
How the Endocrine Society’s Corporate Liaison Board fosters collaboration, fuels innovation, and advances patient care The Endocrine Society (the Society) strives to foster an interdisciplinary community of those practicing, researching, and innovating in endocrinology. Industry is an important site of innovation in endocrinology, and the Society’s Corporate Liaison Board (CLB) plays a pivotal role in...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo...
A precision-medicine protocol for treating acromegaly can slash healthcare costs by 22% while more than doubling a patient’s chances of reaching hormonal remission, according to an economic analysis of the ACROFAST clinical trial. “Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study,” a Spanish study recently published in the...
Honored by both the Endocrine Society and the European Society of Endocrinology with the 2026 Transatlantic Alliance Award, Anna L. Gloyn, DPhil, FMedSci, has made significant contributions to endocrine research on both sides of the Atlantic. Endocrine News speaks with Gloyn about what this award means to her, how a friend in college helped determine...
A Q&A with Executive Editor Mark A. Newman about the exciting next step for the Endocrine Society’s flagship member magazine, Endocrine News. July will mark a historical milestone for Endocrine News magazine as it fully transitions to an online-only publication. The magazine’s Executive Editor, Mark A. Newman, has been leading the publication since 2013 and...
Whether to treat low testosterone in men with obesity will be the topic of “Low Testosterone in Obesity: Should We Treat or Not?” a debate session at ENDO 2026 that is sure to be somewhat vigorous as two experts in the field take sides in a session moderated by Endocrine Society Past-President Stephen Hammes, MD,...
Honored by both the Endocrine Society and the European Society of Endocrinology with the 2026 Transatlantic Alliance Award, Anna L. Gloyn, DPhil, FMedSci, has made significant contributions to endocrine research on both sides of the Atlantic. Endocrine News speaks with Gloyn about what this award means to her, how a friend in college helped determine...
